{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T15:02:34Z","timestamp":1745766154601,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T00:00:00Z","timestamp":1425945600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1038\/nrneph.2015.26","type":"journal-article","created":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T11:59:46Z","timestamp":1425988786000},"page":"257-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of rituximab in challenging nephrotic syndrome"],"prefix":"10.1038","volume":"11","author":[{"given":"Kevin V.","family":"Lemley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,10]]},"reference":[{"key":"BFnrneph201526_CR1","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/ki.2012.280","volume":"82","author":"J Radhakrishnan","year":"2012","unstructured":"Radhakrishnan, J. & Cattran D. C. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines\u2014application to the individual patient. Kidney Int. 82, 840\u2013856 (2012).","journal-title":"Kidney Int."},{"key":"BFnrneph201526_CR2","doi-asserted-by":"publisher","unstructured":"Ravani, P.  et al. Rituximab in children with steroid-dependent nephrotic syndrome: a multicentre, open-label, noninferiority, randomized controlled trial. J. Am. Soc. Nephrol. \n                    http:\/\/dx.doi.org\/10.1681\/ASN.2014080799\n                    \n                   (2015).","DOI":"10.1681\/ASN.2014080799"},{"key":"BFnrneph201526_CR3","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani, P.  et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin. J. Am. Soc. Nephrol. 6, 1308\u20131315 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201526_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima, K.  et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter, double-blind, randomized, placebo-controlled trial. Lancet 384, 1273\u20131281 (2014).","journal-title":"Lancet"},{"key":"BFnrneph201526_CR5","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni, A.  et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 3, 85ra46 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrneph201526_CR6","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s00467-011-1894-x","volume":"26","author":"G Filler","year":"2011","unstructured":"Filler, G.  et al. Should we consider MMF therapy after rituximab for nephrotic syndrome? Pediatr. Nephrol. 26, 1759\u20131762 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph201526_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nm.1857","volume":"9","author":"C Faul","year":"2008","unstructured":"Faul, C.  et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 9, 931\u2013938 (2008).","journal-title":"Nat. Med."},{"key":"BFnrneph201526_CR8","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","volume":"369","author":"CC Yu","year":"2013","unstructured":"Yu, C. C.  et al. Abatacept in B7\u20131-positive proteinuric kidney disease. N. Engl. J. Med. 369, 2416\u20132423 (2013).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2015.26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2015.26","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2015.26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:46:51Z","timestamp":1684471611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2015.26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,10]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["BFnrneph201526"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2015.26","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"type":"print","value":"1759-5061"},{"type":"electronic","value":"1759-507X"}],"subject":[],"published":{"date-parts":[[2015,3,10]]},"assertion":[{"value":"10 March 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}